Pioneering the next frontier in defeating cancer.
Saving lives through early detection.
XEMPERIA is a Swiss biotech startup founded in 2023 as a spin-off from the University of Fribourg, aiming to revolutionize cancer care through innovative blood tests. Leveraging over 25 years of expertise in translational cancer research and biomarker discovery, the company focuses on early detection and monitoring of cancer by identifying cancer-associated biomarkers in the blood using advanced multiomics and AI methodologies.
Their flagship project is a blood test for the early detection of breast cancer, which has successfully completed an initial phase of clinical validation. XEMPERIA is now preparing for a large-scale performance study, with the goal of achieving certification and commercialization by 2028.
Additionally, XEMPERIA is developing DNA-based nanosensors for detecting RNA/DNA, offering rapid, sensitive, and cost-effective cancer detection methods.
Our Vision
is to transform the future of cancer care through advanced blood testing providing patients and doctors with life-saving information at all stages of the diseaseOur Mission
is to deliver innovative, accessible, highly accurate and streamlined blood tests for the early detection and monitoring of cancer enhancing patient outcome and reducing cancer-related mortality
Our Solutions
are based on cutting-edge innovations that redefine what’s possible in cancer diagnostics. Designed to be scalable and adaptable, they apply to a wide range of cancers for early detection, monitoring and therapy choice
